Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Choosing wisely with breast cancer in India
Dr Shona Nag - Sahyadri Hospitals, Pune, India
Choosing wisely with breast cancer in India ( Dr Shona Nag - Sahyadri Hospitals, Pune, India )
20 Feb 2020
EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic...
Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA
EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )
19 Feb 2020
KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC
Dr Julie Graff - Oregon Health & Science University, Portland, USA
KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC ( Dr Julie Graff - Oregon Health & Science University, Portland, USA )
19 Feb 2020
BCG dosing for bladder cancer: Standard frequency schedule correct
Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany
BCG dosing for bladder cancer: Standard frequency schedule correct ( Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany )
19 Feb 2020
RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma
Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA
RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma ( Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA )
19 Feb 2020
CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC
Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA
CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC ( Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA )
19 Feb 2020
Choosing wisely: Lung adenocarcinoma
Dr Navneet Singh - Post Graduate Institute of Medical Education & Research, Chan...
Choosing wisely: Lung adenocarcinoma ( Dr Navneet Singh - Post Graduate Institute of Medical Education & Research, Chandigarh, India )
18 Feb 2020
Integrative molecular characterisation of S/R RCC to reveal determinants of poor...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )
18 Feb 2020
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or ...
Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )
18 Feb 2020
NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advan...
Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom
NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer ( Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom )
18 Feb 2020
NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cel...
Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France
NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cell carcinoma ( Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France )
18 Feb 2020
OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients
Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec
OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients ( Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec )
18 Feb 2020